Sera Prognostics - IR Website

Home

News

Month Year

Investor Alerts

April 27

Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2023 Financial Results on May 10, 2023

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
March 22

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
March 09

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2022 Financial Results on March 22, 2023

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
February 23

SERA PROGNOSTICS TO PRESENT AT UPCOMING MARCH INVESTOR CONFERENCES

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
February 15

Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL

PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay SALT LAKE CITY, Feb. 15, 2023 /PRNewswire/ --

Read More
November 29

FORS MARSH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH SERA PROGNOSTICS

– Sera's PreTRM® test-and-treat strategy helps build on Fors Marsh's commitment to investing in its employees to enable a healthy and viable workforce – SALT LAKE CITY and ARLINGTON, Va.,...

Read More
- Photos 1
November 15

SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA PREDICTING CLINICAL UTILITY AND COST EFFECTIVENESS OF THE PRETRM® TEST-AND-TREAT STRATEGY ACROSS DIVERSE POPULATIONS

- Clinical and economic benefits of the PreTRM® test and treat strategy illustrated amongst diverse racial and ethnic backgrounds - SALT LAKE CITY, Nov. 15, 2022 /PRNewswire/ -- Sera Prognostics...

Read More
November 09

SERA PROGNOSTICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
October 27

Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2022 Financial Results on November 9

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
October 04

SONRAVA HEALTH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH CEREBRAE AND SERA PROGNOSTICS

The value created by applying Sera's PreTRM® test and treat strategy enables savings to be shared in an innovative value-based paradigm SALT LAKE CITY, COPPELL, Texas and SAN MATEO, Calif., Oct....

Read More
September 22

BANNER HEALTH, SERA PROGNOSTICS TEAM UP TO PROVIDE PreTRM® TEST TO COVERED PREGNANT MEMBERS

First and only broadly clinically validated test to provide accurate and actionable information to help reduce the morbidity, mortality, and costs associated with preterm birth Salt Lake City and...

Read More
August 10

SERA PROGNOSTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
July 28

Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2022 Financial Results on August 10

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
June 06

SERA PROGNOSTICS TO PRESENT AT 42nd ANNUAL WILLIAM BLAIR GROWTH STOCK CONFERENCE

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
May 19

SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA DEMONSTRATING IMPROVED PERFORMANCE OF ITS PRETRM® TEST WITH MORE PRECISE GESTATIONAL AGE

Results show that the validated proteomics predictor has even greater predictive performance to determine risk of spontaneous preterm birth SALT LAKE CITY, May 19, 2022 /PRNewswire/ -- Sera...

Read More
May 18

SERA PROGNOSTICS PRESENTS DATA DEMONSTRATING THE HEALTH AND ECONOMIC BENEFIT OF PRETRM® TESTING AT ISPOR ANNUAL MEETING

SALT LAKE CITY, May 18, 2022 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy...

Read More
May 10

SERA PROGNOSTICS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
May 05

SERA PROGNOSTICS AND NEWBORN FOUNDATION PARTNER TO REDUCE RISKS ASSOCIATED WITH PRETERM BIRTH AND IMPROVE HEALTH EQUITY THROUGH THE "EVERY MOTHER, EVERY BABY" PROJECT

Project focused on reducing maternal and neonatal mortality and morbidity by mitigating risks associated with unanticipated preterm birth

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
- Photos 2
May 02

Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2022 Financial Results on May 10

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
April 12

SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF DR. JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD

- Accomplished business and health services leader joins Sera in its quest to improve pregnancy outcomes of mothers and babies - SALT LAKE CITY, April 12, 2022 /PRNewswire/ -- Sera Prognostics...

Read More
- Photos 1
March 29

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2021 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
March 18

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2021 Financial Results on March 29

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
March 03

SERA PROGNOSTICS TO PRESENT AT UPCOMING MARCH INVESTOR CONFERENCES

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
February 17

SERA PROGNOSTICS PRESENTATION RESCHEDULED FOR CITI 2022 HEALTHCARE CONFERENCE

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
February 07

SERA PROGNOSTICS TO PRESENT AT UPCOMING FEBRUARY INVESTOR CONFERENCES

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More

Show per page

Email Alerts